BIOMARIN PHARMACEUTICAL INC

Form 4

October 03, 2007

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF

OMB Number:

3235-0287

Expires:

January 31, 2005

0.5

Estimated average burden hours per

OMB APPROVAL

response...

if no longer subject to Section 16. Form 4 or Form 5

Check this box

SECURITIES Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934, obligations Section 17(a) of the Public Utility Holding Company Act of 1935 or Section may continue.

See Instruction 1(b).

(Print or Type Responses)

1. Name and Address of Reporting Person * Swiedler Stuart J

2. Issuer Name and Ticker or Trading Symbol

30(h) of the Investment Company Act of 1940

5. Relationship of Reporting Person(s) to

Issuer

BIOMARIN PHARMACEUTICAL

INC [BMRN]

(Check all applicable)

SVP, Clinical Affairs

(Last) (First) (Middle)

> (Month/Day/Year) 10/01/2007

Director 10% Owner X_ Officer (give title Other (specify below)

C/O BIOMARIN PHARMACEUTICAL INC., 105

(Street)

DIGITAL DRIVE

4. If Amendment, Date Original

3. Date of Earliest Transaction

6. Individual or Joint/Group Filing(Check

Applicable Line)

Filed(Month/Day/Year)

X Form filed by One Reporting Person Form filed by More than One Reporting

Person

NOVATO, CA 94949

(City)	(State)	(Zip) Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned							
1.Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transactic Code (Instr. 8)	4. Securit our Dispos (Instr. 3, 4	ed of		5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
Common Stock	10/01/2007(1)	10/01/2007	M	2,500	A	\$ 4	12,500	D	
Common Stock	10/01/2007(1)	10/01/2007	M	10,000	A	\$ 6.13	22,500	D	
Common Stock	10/01/2007(1)	10/01/2007	S	1,202	D	\$ 24.9	21,298	D	
Common Stock	10/01/2007(1)	10/01/2007	S	48	D	\$ 24.91	21,250	D	
	10/01/2007(1)	10/01/2007	S	1,250	D	\$ 24.99	20,000	D	

Edgar Filing: BIOMARIN PHARMACEUTICAL INC - Form 4

Common Stock								
Common Stock	10/01/2007(1)	10/01/2007	S	644	D	\$ 25	19,356	D
Common Stock	10/01/2007(1)	10/01/2007	S	100	D	\$ 25.0001	19,256	D
Common Stock	10/01/2007(1)	10/01/2007	S	1,250	D	\$ 25.075	18,006	D
Common Stock	10/01/2007(1)	10/01/2007	S	1,756	D	\$ 25.1	16,250	D
Common Stock	10/01/2007(1)	10/01/2007	S	1,250	D	\$ 25.1101	15,000	D
Common Stock	10/01/2007(1)	10/01/2007	S	1,250	D	\$ 25.1301	13,750	D
Common Stock	10/01/2007(1)	10/01/2007	S	1,250	D	\$ 25.1401	12,500	D
Common Stock	10/01/2007(1)	10/01/2007	S	1,250	D	\$ 25.22	11,250	D
Common Stock	10/01/2007(1)	10/01/2007	S	1,250	D	\$ 25.3	10,000	D

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

Persons who respond to the collection of SEC 1474 information contained in this form are not required to respond unless the form displays a currently valid OMB control number.

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)

1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transacti Code (Instr. 8)	5. Number of orDerivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4, and 5)	6. Date Exercisab Expiration Date (Month/Day/Year		7. Title and Amount o Underlying Securities (Instr. 3 and 4)	
				Code V	(A) (D)	Date Exercisable	Expiration Date	Title	Amount or Number of Share
Stock Option (right to buy)	\$ 4	10/01/2007	10/01/2007	M	2,500	12/24/1998(2)	06/14/2008	Common Stock	2,500

(9-02)

Stock

Option (right to buy)

\$ 6.13 10/01/2007 10/01/2007

M

 $10,000 \quad 07/07/2005^{(3)} \quad 01/06/2015$

Common

Stock

10,000

Reporting Owners

Reporting Owner Name / Address

Relationships

10% Owner Director

Officer

Other

Swiedler Stuart J C/O BIOMARIN PHARMACEUTICAL INC.

105 DIGITAL DRIVE **NOVATO, CA 94949**

SVP. Clinical **Affairs**

Signatures

/s/ G. Eric Davis, Attorney-in-Fact

10/03/2007

**Signature of Reporting Person

Date

Explanation of Responses:

- If the form is filed by more than one reporting person, see Instruction 4(b)(v).
- Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
- (1) Transaction made pursuant to a Rule 10b5-1 Trading Plan.
- (2) Options vested 6/48ths on 12/24/1998 and 1/48th on the 24th of each month thereafter.
- (3) Options vested 6/48ths on 7/7/2005 and 1/48th on the 7th of each month thereafter.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure. Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.

Reporting Owners 3